as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti
Company profile
Ticker
RVTY
Exchange
Website
CEO
Prahlad Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EG&G INC, PERKINELMER INC
SEC CIK
Corporate docs
Subsidiaries
2Cure, LLC • BioLegend CNS, Inc. • BioLegend, Inc. • BioLegend Ventures, LLC • Caliper Life Sciences, Inc. • Cambridge Research • Dharmacon, Inc. • Horizon Discovery, Inc. • Oxford Immunotec USA, Inc. • Qognit, Inc. ...
IRS number
42052042
RVTY stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Revvity Announces Financial Results for the First Quarter of 2024
29 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
24 Apr 24
ARS
2023 FY
Annual report to shareholders
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
13 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Results of Operations and Financial Condition
1 Feb 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
Results of Operations and Financial Condition
9 Jan 24
Transcripts
RVTY
Earnings call transcript
2024 Q1
29 Apr 24
RVTY
Earnings call transcript
2023 Q4
1 Feb 24
RVTY
Earnings call transcript
2023 Q3
30 Oct 23
RVTY
Earnings call transcript
2023 Q2
1 Aug 23
RVTY
Earnings call transcript
2023 Q2
1 Aug 23
RVTY
Earnings call transcript
2023 Q1
11 May 23
RVTY
Earnings call transcript
2023 Q1
11 May 23
RVTY
Earnings call transcript
2022 Q4
14 Feb 23
RVTY
Earnings call transcript
2022 Q3
8 Nov 22
RVTY
Earnings call transcript
2022 Q3
8 Nov 22
Latest ownership filings
144
Notice of proposed sale of securities
15 May 24
4
Sophie V. Vandebroek
2 May 24
4
Peter Barrett
2 May 24
4
Pascale Witz
2 May 24
4
Samuel R. Chapin
2 May 24
4
Frank Witney
2 May 24
4
Michel Vounatsos
2 May 24
4
Michelle McMurry-Heath
2 May 24
4
Michael A Klobuchar
2 May 24
4
ALEXIS P MICHAS
2 May 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.14 bn | 1.14 bn | 1.14 bn | 1.14 bn | 1.14 bn | 1.14 bn |
Cash burn (monthly) | 65.12 mm | (no burn) | (no burn) | (no burn) | 11.16 mm | (no burn) |
Cash used (since last report) | 494.07 mm | n/a | n/a | n/a | 84.68 mm | n/a |
Cash remaining | 643.89 mm | n/a | n/a | n/a | 1.05 bn | n/a |
Runway (months of cash) | 9.9 | n/a | n/a | n/a | 94.4 | n/a |
Institutional ownership, Q4 2023
44.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 379 |
Opened positions | 45 |
Closed positions | 160 |
Increased positions | 128 |
Reduced positions | 147 |
13F shares | Current |
---|---|
Total value | 5.80 tn |
Total shares | 54.70 mm |
Total puts | 3.80 k |
Total calls | 20.50 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 14.18 mm | $1.55 tn |
Capital Research Global Investors | 7.67 mm | $838.08 bn |
STT State Street | 5.18 mm | $566.74 bn |
MS Morgan Stanley | 2.33 mm | $254.27 bn |
Independent Franchise Partners | 1.93 mm | $210.52 bn |
Mitsubishi UFJ Kokusai Asset Management | 1.79 mm | $188.37 bn |
IVZ Invesco | 1.52 mm | $165.87 bn |
Pictet Asset Management Holding | 1.28 mm | $139.80 bn |
NTRS Northern Trust | 1.17 mm | $127.40 bn |
Dimensional Fund Advisors | 1.02 mm | $112.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Witz Pascale | Common Stock | Grant | Acquire A | No | No | 0 | 1,218 | 0.00 | 11,293 |
1 May 24 | Witz Pascale | Common Stock | Grant | Acquire A | No | No | 0 | 977 | 0.00 | 10,075 |
1 May 24 | Barrett Peter | Common Stock | Grant | Acquire A | No | No | 0 | 1,218 | 0.00 | 23,601 |
1 May 24 | Barrett Peter | Common Stock | Grant | Acquire A | No | No | 0 | 977 | 0.00 | 22,383 |
1 May 24 | Witney Frank | Common Stock | Grant | Acquire A | No | No | 0 | 1,218 | 0.00 | 18,662 |
1 May 24 | Witney Frank | Common Stock | Grant | Acquire A | No | No | 0 | 977 | 0.00 | 17,444 |
1 May 24 | Vandebroek Sophie V. | Common Stock | Grant | Acquire A | No | No | 0 | 1,218 | 0.00 | 2,676 |
1 May 24 | Vandebroek Sophie V. | Common Stock | Grant | Acquire A | No | No | 0 | 977 | 0.00 | 1,458 |
1 May 24 | Chapin Samuel R. | Common Stock | Grant | Acquire A | No | No | 0 | 1,218 | 0.00 | 17,984 |
1 May 24 | Chapin Samuel R. | Common Stock | Grant | Acquire A | No | No | 0 | 977 | 0.00 | 16,766 |
News
Baird Maintains Outperform on Revvity, Raises Price Target to $127
30 Apr 24
TD Cowen Maintains Buy on Revvity, Raises Price Target to $130
30 Apr 24
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
29 Apr 24
Revvity Q1 2024 Adj EPS $0.98 Beats $0.93 Estimate, Sales $649.920M Beat $646.843M Estimate
29 Apr 24
Enphase Energy Reports Weak Results, Joins Lithia Motors And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
24 Apr 24
Press releases
Revvity Announces Financial Results for the First Quarter of 2024
29 Apr 24
Revvity Board Declares Quarterly Dividend
25 Apr 24
Revvity to Present at BofA Securities 2024 Health Care Conference
25 Apr 24
Revvity Unveils a New Era of Automated Tuberculosis Testing
24 Apr 24
Revvity Signals Software's New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners
15 Apr 24